Development and Analysis of Replication-Deficient CMV Vectors
复制缺陷型 CMV 载体的开发和分析
基本信息
- 批准号:8117930
- 负责人:
- 金额:$ 43.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-15 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS VaccinesAIDS/HIV problemAcuteAdultAnimal ModelAnimalsAntigensAttenuatedCharacteristicsClinical TrialsCytomegalovirusCytomegalovirus InfectionsDataDevelopmentEconomic InflationEssential GenesFutureGenesGenomeGoalsGrowthHIVHIV vaccineHumanImmuneImmune responseImmunityImmunizationImmunocompromised HostImmunosuppressionIn VitroIndividualInfectionInstructionMacaca mulattaMaintenanceMemoryModelingMurid herpesvirus 1MusOutcome StudyPathogenesisPathogenicityPerformancePopulationPregnant WomenPreparationPrincipal InvestigatorProductionProteinsPublishingRecombinant VaccinesRecombinantsRoleSIVSafetySiteStem cell transplantSurfaceT cell responseT memory cellT-LymphocyteTestingVaccinesViralViral AntigensViral PathogenesisVirusVirus DiseasesVirus Sheddingattenuationbasedesignfetalimmunogenicityin vivoin vivo Modelinsightlatent infectionnovelpreventresponsevector
项目摘要
Cytomegalovirus (CMV)-based vectors are uniquely capable of inducing longterm effector memory T cell
responses and escaping vector-specific immunity. However, fully replicative vectors are unlikely to be
approved for human use given the pathogenic potential of CMV, particularly in pregnant women and
immunocompromised individuals. A central goal is therefore to increase vector safety while maintaining
immunogenicity and efficacy. In this project, we will define how acute and persistent replication correlates
with the ability of rhesus CMV to induce a T cell response to simian immunodeficiency virus (SIV).
Preliminary data suggest that severely attenuated RhCMV can still induce CMV-specific immune responses
in sero-negafive animals consistent with persistent antigen production. Unlike the parental vector however,
the such low-cycle vectors do not seem to be secreted from inoculated animals. Importanfiy, low-cycle
vectors expressing simian immunedeficiency virus (SIV) antigens super-infect sero-positive animals and
induce an SIV-specific T cell response suggesfing retention of immunogenicity. In three specific aims we will
determine the extent to which vectors can be rendered replication-incompetent without sacrificing
immunogenicity and the pathogenicity of such vectors in the immunocompromised. Specific Aim 1 is to
further reduce the ability of RhCMV/SIV vectors to replicate by construcfing single-cycle vectors. In addifion,
we will construct vectors whose replication can be externally controlled thus allowing us to study the role of
viral replicafion and spreading for the establishment and maintenance of persistent anfigen producfion and T
cell stimulation. Specific Aim 2 is to determine the pathogenicity of replicafion-deficient vectors in an animal
model of congenital infecfion. A further aim is to compare their ability to induce robust SIV-specific effector
memory T cell responses in sero-positive animals. Specific Aim 3 is to generate vectors combining the
lowest pathogenicity with the highest immunogenicity for efficacy studies and to confirm that corresponding
human CMV vectors are attenuated in a novel animal model of latent infection. Thus, we expect that the
attenuation strategy developed here will be direcfiy translatable into HCMV/HIV vectors.
RELEVANCE (See instructions):
The goal of this project is to increase the safety of an HIV vaccine delivered by cytomegalovirus. This will be
achieved by removing essential genes from the cytomegalovirus genome thus generating a replicafion-
deficient vaccine. We will test whether the resulfing vaccine is safe while retaining the advantageous
immunizing characteristics of the replicating vaccine.
PROJECT/PERFORIVIANCE SITE(S) (if additional space is needed, use Project/Perfonmance Site Fomnat Page)
Project/Performance
基于巨细胞病毒(CMV)的载体具有诱导长期效应记忆T细胞的独特能力
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Klaus J Fruh其他文献
Klaus J Fruh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Klaus J Fruh', 18)}}的其他基金
Non-canonical epitope presentation and antigen processing by MHC-E
MHC-E 的非典型表位呈递和抗原加工
- 批准号:
10801509 - 财政年份:2023
- 资助金额:
$ 43.54万 - 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
- 批准号:
9982274 - 财政年份:2017
- 资助金额:
$ 43.54万 - 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
- 批准号:
9238234 - 财政年份:2017
- 资助金额:
$ 43.54万 - 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
- 批准号:
9751633 - 财政年份:2017
- 资助金额:
$ 43.54万 - 项目类别:
An Effector Memory T Cell-Inducing Subunit Vaccine against Malaria
一种针对疟疾的效应记忆 T 细胞诱导亚单位疫苗
- 批准号:
8607501 - 财政年份:2013
- 资助金额:
$ 43.54万 - 项目类别:
An Effector Memory T Cell-Inducing Subunit Vaccine against Malaria
一种针对疟疾的效应记忆 T 细胞诱导亚单位疫苗
- 批准号:
8423271 - 财政年份:2013
- 资助金额:
$ 43.54万 - 项目类别:
MECHANISMS OF IMMUNE VULNERABILITY OF THE ELDERLY TO THE WEST NILE VIRUS
老年人对西尼罗河病毒免疫脆弱的机制
- 批准号:
8357751 - 财政年份:2011
- 资助金额:
$ 43.54万 - 项目类别:
EVASION OF ANTIGEN PRESENTATION BY RHESUS CYTOMEGALOVIRUS
恒河猴巨细胞病毒逃避抗原呈递
- 批准号:
8357750 - 财政年份:2011
- 资助金额:
$ 43.54万 - 项目类别:
MODULATION OF INNATE IMMUNE RESPONSES BY CYTOMEGALOVIRUS
巨细胞病毒对先天免疫反应的调节
- 批准号:
8357775 - 财政年份:2011
- 资助金额:
$ 43.54万 - 项目类别:
Kianse Networks Controling Flavivirus Replication
Kianse Networks 控制黄病毒复制
- 批准号:
8234067 - 财政年份:2011
- 资助金额:
$ 43.54万 - 项目类别:














{{item.name}}会员




